Allogene Therapeutics ALLO 深 沪
等待开盘 08-15 09:30:00 美东时间
1.07
+0.030
+2.88%
华盛通- 最 高1.085
- 今 开1.05
- 成交量 813.83万股
- 最 低 0.9901
- 昨 收 1.04
- 总市值 2.34亿
- 52周最高 3.78
- 市盈率 静 --
- 换手率 3.72%
- 52周最低 0.8621
- 委 比 1.18%
- 总股本 2.19亿
- 历史最高 55.00
- 量 比 1.67
- 振 幅 9.13%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Therapeutics Advances in CAR T Cell Therapy
Allogene Therapeutics ( ($ALLO) ) has released its Q2 earnings. Here is a break...
08-14 11:57
Allogene Therapeutics Q2 EPS $(0.23) Beats $(0.28) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 18.15 percent. This is a 34.29 percent increase over losses of $(0.35) per share
08-14 04:38
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look at Allogene Therapeutics's Upcoming Earnings Report
Allogene Therapeutics (NASDAQ:ALLO) is preparing to release its quarterly earni...
08-13 02:02
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics will report its Q2 2025 financial results and provide a business update on August 13, 2025, followed by a live webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The listen-only webcast will be available at www.allogene.com under the Investors tab, with a replay accessible for 30 days. To ask questions during the call, registration is required via a provided link to receive a personal PIN. Allogene, headquartered in S...
08-06 12:30
JMP Securities Reiterates Market Perform on Allogene Therapeuticsto Market Perform
JMP Securities analyst Reni Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Market Perform.
08-04 22:28
JP Morgan Downgrades Allogene Therapeutics to Neutral
JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Overweight to Neutral.
08-04 18:00
Allogene Therapeutics Selects Selected Standard Fludarabine And Cyclophosphamide As Lymphodepletion Regimen To Be Used In ALPHA3 Study Evaluating Cemacabtagene Ansegedleucel In First-line Consolidation For Large B-Cell Lymphoma
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA
08-01 20:37
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Allogene Therapeutics announced the selection of standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study, following a Grade 5 adverse event linked to ALLO-647. The FC arm will now proceed as a randomized study comparing cema-cel to observation. No further enrollment in the FCA arm, which included ALLO-647, will occur due to safety concerns. The Company has shifted its focus to its next-generation Dagger®...
08-01 12:30
Multiple Insiders Sold Allogene Therapeutics Shares Presenting Weak Signs For Investors
Allogene Therapeutics, Inc. (NASDAQ:ALLO) shareholders might have a reason to w...
07-24 18:12
